(NASDAQ: CLGN) Collplant Biotechnologies's forecast annual revenue growth rate of 28.53% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Collplant Biotechnologies's revenue in 2024 is $10,959,000.On average, 1 Wall Street analysts forecast CLGN's revenue for 2024 to be $32,411,062, with the lowest CLGN revenue forecast at $32,411,062, and the highest CLGN revenue forecast at $32,411,062. On average, 1 Wall Street analysts forecast CLGN's revenue for 2025 to be $166,063,744, with the lowest CLGN revenue forecast at $166,063,744, and the highest CLGN revenue forecast at $166,063,744.
In 2026, CLGN is forecast to generate $259,861,128 in revenue, with the lowest revenue forecast at $259,861,128 and the highest revenue forecast at $259,861,128.